Tarsus Pharmaceuticals acquired Alkeus Pharmaceuticals for $450 million to add gildeuretinol (ALK-001), an oral therapy for Stargardt disease, to its pipeline. The candidate has shown structural and functional improvements over seven years of patient follow-up, with Phase 3 data expected in 2029.
Key Points
- ALK-001 demonstrates long-term tolerability across 400+ patients over seven years
- Phase 3 NORTHSTAR trial will measure lesion growth and visual function over 24 months
- Acquisition positions Tarsus to commercialize first disease-modifying treatment for Stargardt
Longevity Analysis
Stargardt disease causes progressive central vision loss in younger adults and remains without effective disease-modifying treatment. A compound that slows structural degeneration and preserves visual function addresses a significant gap in preserving quality of life and independence during the productive years. The seven-year safety data represents critical evidence that therapeutic intervention can sustain tissue integrity without cumulative toxicity—a foundation for understanding whether similar approaches might extend healthspan in other degenerative conditions affecting sensory systems.
Original published by LT Wire.